依达拉奉治疗急性一氧化碳中毒后迟发性脑病的临床疗效及对SOD和MDA的影响

Clinical efficacy of edaravone in treatment of delayed encephalopathy after acute carbon monoxide poisoning and its effect on SOD and MDA

目的探讨依达拉奉治疗急性一氧化碳中毒后迟发性脑病(DEACMP)的临床疗效,以及对血清超氧化物歧化酶(SOD)活性及丙二醛(MDA)水平的影响。方法将60例患者随机分为观察组和对照组各30例,2组患者均给予常规和高压氧治疗,观察组加用依达拉奉。结果治疗1个月后,观察组患者总有效率96.67%,高于对照组的76.67%,差异有统计学意义(P<0.05)。2组患者血清SOD和MDA水平均得到改善(P<0.05),但观察组患者血清SOD水平升高和MDA下降幅度更大(P<0.05)。结论 DEACMP在常规治疗基础上加用依达拉奉,可显著提高效果,促进神经功能恢复,值得临床推广应用。

Objective To explore the clinical efficacy of edaravone in the treatment of delayed encephalopathy after acute carbon monoxide poisoning （DEACMP） and its effect on SOD and MDA. Methods Totally 60 patient were divided randomly into the intervention group （30 cases） and control group （30 cases）, all patients received conventional therapy and hyperbaric oxygen therapy, the patients in intervention group received additional edaravone. Results After one month of treatment, the total effective rate was 96.67%in intervention group and 76.67% in control group, it was significantly different （P〈0.05）. The levels of serum SOD and MDA in the patients were improved after treatment, but the levels of serum SOD and MDA de- clined greater in observation group, there were significant differences（P〈0.05）. Conclusion Edaravone combined conventional therapy, hyperbaric oxygen therapy for patients with DEACMP is effective and safe, and promote the recovery of neurological function and is worthy of clinical popularizing and apphcation.